AA
ELDN icon

ALPS Advisors’s Eledon Pharmaceuticals ELDN Stock Holding History

ALPS Advisors’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-44,436
Closed -$151K – 1036
2025
Q1 		$151K Sell
44,436
-3,874
-8% -$15.9K ﹤0.01% 971
2024
Q4 		$199K Buy
+48,310
New +$190K ﹤0.01% 973
2016
Q2 		– Sell
-157
Closed -$142K – 624
2016
Q1 		$142K Sell
157
-27
-15% -$26.5K ﹤0.01% 613
2015
Q4 		$259K Sell
184
-33
-15% -$57.5K ﹤0.01% 660
2015
Q3 		$3.63K Buy
217
+80
+58% +$165K ﹤0.01% 638
2015
Q2 		$296K Buy
+137
New +$265K ﹤0.01% 656

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

ALPS Advisors's ELDN Position: Q2 2025 in Review

ALPS Advisors sold out of Eledon Pharmaceuticals (ELDN) in Q2 2025, closing a stake of 44,436 shares — an estimated $151K sold.

ALPS Advisors first reported a position in ELDN in Q2 2015 and held it in 6 quarters. The position peaked at $296K in Q2 2015. 85 funds tracked by Wall St. Rank hold ELDN as of Q2 2025.

  • ALPS Advisors reported no remaining Eledon Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • ALPS Advisors sold 44,436 Eledon Pharmaceuticals shares in Q2 2025, an estimated $151K.
  • ALPS Advisors first reported a position in Eledon Pharmaceuticals in Q2 2015 and held it in 6 quarters.
  • ALPS Advisors's Eledon Pharmaceuticals position peaked at $296K in Q2 2015.
  • 85 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2025.

Based on ALPS Advisors's 13F filing for Q2 2025, filed 11 Aug 2025.